Roche’s Polivy (polatuzumab vedotin) Receives Health Canada’s Approval For R/R Diffuse Large B Cell Lymphoma

Shots:

• Health Canada, under (NOC/c) policy, has granted market authorization to Polivy + bendamustine and rituximab (BR) for six 21-day cycles in adult patients with r/r DLBCL, who are not eligible for ASCT and prior treated with at least one therapy
• The approval is based on P-I/II GO29365 study assessing Polivy + BR vs BR alone in 80 patients, including 4 Canadians with previously treated DLBCL.  Results: patients achieving CR or PR (40% vs 18%); mDoR (12.6 vs 7.7mos.)
• Polivy is an ADC, targeting CD79b and destroys the B cells through the delivery of an anti-cancer agent, while minimizing the effects on normal cells

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: The Hindu